ClinicalTrials.gg
Status unknownNCT05332665Updated Apr 18, 2022

AS-OCT Evaluation of Iridocorneal Angle of Patients of Angle Closure Glaucoma After Phacoemulsification

An observational study in Glaucoma, Angle-Closure, sponsored by Minia University. Status unknown at 1 site in Egypt. Open to participants aged 30 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-04-18.

Sponsored by Minia University · Observational

The sponsor has not verified this record recently (last verified Apr 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
15
Ages
30 Years to 60 Years
Sex
All
01

Study summary

Evaluation of the effect of phacoemulsification and YAG Laser peripheral iridotomy on the anterior chamber angle anatomic parameters in PACG eyes, using anterior segment optical coherence tomography (SS ASOCT) device

Read the detailed description

The recent treatment of ACG is phacoemulsification in patients of acute attack with YAG laser iridotomy in the other eye.

The AS-OCT will be used for evaluation of the angle of the anterior chamber parameters in both eyes after phacoemulsification and YAG laser peripheral iridotomy.

Follow up of AS-OCT will be done 1,3,6 months after surgery and we will compare results in each eye and between both eyes.

.

02

Conditions studied

  • Glaucoma, Angle-Closure
03

In context

Glaucoma, Angle-Closure

91 studies on the registry are indexed under Glaucoma, Angle-Closure; 17 are open to participants now.

This study's planned enrollment of 15 is below the median of 225 across 32 observational studies indexed under Glaucoma, Angle-Closure.

Browse Glaucoma, Angle-Closure studies →

Lead sponsor

Minia University is the lead sponsor of 370 studies on the registry; 117 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with acute attack of ACG with phacoemulsification in this eye with YAG laser PI in the other eye

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with acute attack of angle closure glaucoma in one eye.
  • Patients fit for phacoemulsification

Exclusion criteria

Exclusion Criteria:

  • 1- Patients with history of any intraocular surgery. 2- Patients with history of refractive surgery. 3- Patients with diabetic retinal vasculopathy or retinal detachment. 4- Patients with chronic angle closure glaucoma, open angle glaucoma or 2ry glaucoma
05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
15 participants (estimated)
Patient registry
No

Groups and cohorts

  • Angle opening distance (AOD)

    The AOD measured as perpendicular distance between anterior iris surface and point at trabecular meshwork at 500 μm anterior to the scleral spur

    Device: AS-OCT · Procedure: YAG laser PI

  • Trabecular iris space area (TISA) 500

    TISA 500 was measured as an area bounded anteriorly by the AOD 500, posteriorly by a line drawn from the scleral spur perpendicular to the plane of the inner scleral wall to the opposing iris, superiorly by the inner corneoscleral wall, and inferiorly by the iris surface

    Device: AS-OCT · Procedure: YAG laser PI

  • Anterior chamber depth (ACD)

    The ACD was measured as the perpendicular distance from the corneal endothelium at the corneal apex to the anterior lens surface

    Device: AS-OCT · Procedure: YAG laser PI

Interventions

  • DeviceAS-OCT

    Anterior segment optical coherence tomography (AS OCT) is an imaging device that can acquire an anterior segment image using a noncontact method with the patient in a sitting position. This device provides reproducible and quantitative measurements of the AC angle and other anterior segment parameters.

  • ProcedureYAG laser PI

    medical procedure which uses a laser device to create a hole in the iris, thereby allowing aqueous humor to traverse directly from the posterior to the anterior chamber and, consequently, relieve a pupillary block

06

What researchers measure

Primary outcomes

  1. IOP

    mmhg

    Time frame: up to 6 months

Secondary outcomes

  1. Corneal endothelial count

    CD per mm2

    Time frame: up to 6 months

07

Study locations

1 of 1 sites recruiting
  • mohamed Mahmoud
    Minia, El Minia 61111, Egypt
    Recruiting
    • mohamed Mahmoud · Contact
08

References and documents

Individual participant data

Plan to share: No — Not decided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2022 (actual). Primary completion is estimated for Dec 2022, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2022
First posted
Apr 18, 2022
StartActual
Jan 11, 2022
Primary completionEst.
Dec 2022
CompletionEst.
Dec 2022
Last update
Apr 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05332665
Lead sponsor
Minia University
Responsible party
Mohamed Salah (Principal Investigator, Minia University) — Principal investigator
First posted
Apr 18, 2022
Start date
Jan 11, 2022
Primary completion
Dec 2022 (estimated)
Completion
Dec 2022 (estimated)
Last update
Apr 18, 2022

Study contacts

mohamed Salah
Contact
drmsalah1982@yahoo.com
01003321802
mohamed Salah
principal investigator · Minia faculty of medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion